150P Adjuvant BEP/EP versus carboplatin-paclitaxel in adult granulosa cell tumor of the ovary: A multicenter analysis of survival and toxicity
Articles > Article · 2026
Authors: A. Gecgel, M. Uzun, M.B. Kaya, S. Ay, T. Ugur, T. Kaya, Y.E. Surgen, E. Kavvasoglu Durmus, C. Kelten Talu, Z. Arik, O. Sutcuoglu, E. Goker, S. Ön
ESMO Open, International, WoS, 2026, vol 11, pp 108197-108197
DOI: 10.1016/j.esmoop.2026.108197
Summary
Adult granulosa cell tumors (AGCTs) are rare ovarian sex cord-stromal tumors, and the role of adjuvant chemotherapy remains uncertain. We compared disease-free survival (DFS) and toxicity between bleomycin-etoposide-cisplatin/etoposide-cisplatin (BEP/EP) and carboplatin-paclitaxel (CP).